1. Search Result
Search Result
Pathways Recommended: Vitamin D Related/Nuclear Receptor
Results for "

Protein kinase D

" in MedChemExpress (MCE) Product Catalog:

80

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

15

Natural
Products

25

Recombinant Proteins

17

Isotope-Labeled Compounds

5

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151372

    PKD Cancer
    Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC50 values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation .
    Protein kinase D inhibitor 1
  • HY-E70762

    PDGFR Cancer
    PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha D842V is a mutant of PDGFRalpha. PDGFRalpha D842V Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha D842V protein that can be used to study PDGFRalpha D842V-related functions .
    PDGFRalpha D842V Recombinant Human Active Protein Kinase
  • HY-E70764

    PDGFR Cancer
    PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha V561D is a mutant of PDGFRalpha. PDGFRalpha V561D Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha V561D protein that can be used to study PDGFRalpha V561D-related functions .
    PDGFRalpha V561D Recombinant Human Active Protein Kinase
  • HY-E70723

    FLT3 Cancer
    FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 D835Y is the most frequent kinase domain mutation, converting aspartic acid to tyrosine. FLT3 D835Y Recombinant Human Active Protein Kinase is a recombinant FLT3 D835Y protein that can be used to study FLT3 D835Y-related functions .
    FLT3 D835Y Recombinant Human Active Protein Kinase
  • HY-E70749

    c-Met/HGFR Cancer
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions .
    MET D1228N Recombinant Human Active Protein Kinase
  • HY-E70748

    c-Met/HGFR Cancer
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions .
    MET D1228H Recombinant Human Active Protein Kinase
  • HY-E70756

    c-Met/HGFR Cancer
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230D is a mutant of MET. MET Y1230D Recombinant Human Active Protein Kinase is a recombinant MET Y1230D protein that can be used to study MET Y1230D-related functions .
    MET Y1230D Recombinant Human Active Protein Kinase
  • HY-E70758

    c-Met/HGFR Cancer
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .
    MET Y1235D Recombinant Human Active Protein Kinase
  • HY-E70703

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d752-759 Recombinant Human Active Protein Kinase is a recombinant EGFR d752-759 protein that can be used to study EGFR d752-759-related functions .
    EGFR d752-759 Recombinant Human Active Protein Kinase
  • HY-E70697

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750 Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750 protein that can be used to study EGFR d746-750-related functions .
    EGFR d746-750 Recombinant Human Active Protein Kinase
  • HY-E70736

    c-Kit Cancer
    KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT D816V is a mutant of KIT. KIT D816V Recombinant Human Active Protein Kinase is a recombinant KIT D816V protein that can be used to study KIT D816V-related functions .
    KIT D816V Recombinant Human Active Protein Kinase
  • HY-E70735

    c-Kit Cancer
    KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT D816H is a mutant of KIT. KIT D816H Recombinant Human Active Protein Kinase is a recombinant KIT D816H protein that can be used to study KIT D816H-related functions .
    KIT D816H Recombinant Human Active Protein Kinase
  • HY-E70738

    c-Kit Cancer
    KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D is a mutant of KIT. KIT V559D Recombinant Human Active Protein Kinase is a recombinant KIT V559D protein that can be used to study KIT V559D-related functions .
    KIT V559D Recombinant Human Active Protein Kinase
  • HY-E70797

    CaMK Cardiovascular Disease
    CAMK2 is involved in the regulation of cellular processes in a variety of tissues. One member, CAMK2δ CAMK2D is involved in vasopressin signaling in the renal collecting duct, which controls water excretion through regulation of the water channel aquaporin-2 (AQP2). Biotin-CaMK2δ CAMK2D Recombinant Human Active Protein Kinase is obtained by expressing CaMK2δ CAMK2D proteins and is biotinylated .
    Biotin-CaMK2δ CAMK2D Recombinant Human Active Protein Kinase
  • HY-E70701

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-749/A750P Recombinant Human Active Protein Kinase is a recombinant EGFR d747-749/A750P protein that can be used to study EGFR d747-749/A750P-related functions .
    EGFR d747-749/A750P Recombinant Human Active Protein Kinase
  • HY-E70698

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/C797S protein that can be used to study EGFR d746-750/C797S-related functions .
    EGFR d746-750/C797S Recombinant Human Active Protein Kinase
  • HY-E70702

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-752/P753S Recombinant Human Active Protein Kinase is a recombinant EGFR d747-752/P753S protein that can be used to study EGFR d747-752/P753S-related functions .
    EGFR d747-752/P753S Recombinant Human Active Protein Kinase
  • HY-151374

    PKD Cancer
    3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC50 values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer .
    3-IN-PP1
  • HY-E70740

    c-Kit Cancer
    KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D/V654A is a mutant of KIT. KIT V559D/V654A Recombinant Human Active Protein Kinase is a recombinant KIT V559D/V654A protein that can be used to study KIT V559D/V654A-related functions .
    KIT V559D/V654A Recombinant Human Active Protein Kinase
  • HY-E70739

    c-Kit Cancer
    KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D/T670I is a mutant of KIT. KIT V559D/T670I Recombinant Human Active Protein Kinase is a recombinant KIT V559D/T670I protein that can be used to study KIT V559D/T670I-related functions .
    KIT V559D/T670I Recombinant Human Active Protein Kinase
  • HY-E70699

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S protein that can be used to study EGFR d746-750/T790M/C797S-related functions .
    EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase
  • HY-E70700

    EGFR Cancer
    EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S/L858R protein that can be used to study EGFR d746-750/T790M/C797S/L858R-related functions .
    EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase
  • HY-N14638

    EGFR Infection
    Paeciloquinone D can inhibit the EGFR protein tyrosine kinase .
    Paeciloquinone D
  • HY-N14689

    Src Infection Cancer
    Hibarimicin D is a tyrosine kinase inhibitor. Hibarimicin D selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin D also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .
    Hibarimicin D
  • HY-101047S

    Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7

    PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine-d7 is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine-d7
  • HY-101047
    D-erythro-Sphingosine
    4 Publications Verification

    Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine

    PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine
  • HY-101047S1

    Erythrosphingosine-13C2,d2; erythro-C18-Sphingosine-13C2,d2; trans-4-Sphingenine-13C2,d2

    Isotope-Labeled Compounds PKC Endogenous Metabolite Phosphatase Cancer
    D-erythro-Sphingosine-13C2,d2 is a deuterated labeled D-erythro-Sphingosine . D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator .
    D-erythro-Sphingosine-13C2,d2
  • HY-101047R

    Erythrosphingosine (Standard); erythro-C18-Sphingosine (Standard); trans-4-Sphingenine (Standard)

    Reference Standards PKC Phosphatase Endogenous Metabolite Cancer
    D-erythro-Sphingosine (Standard) is the analytical standard of D-erythro-Sphingosine. This product is intended for research and analytical applications. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].
    D-erythro-Sphingosine (Standard)
  • HY-129330

    PKC Others
    Sapintoxin D is a fluorescent phorbol ester that can be used to study the activation of protein kinase C (PKC). Sapintoxin D is a calcium-dependent PKC activator .
    Sapintoxin D
  • HY-159846S

    Isotope-Labeled Compounds MEK Cancer
    Luvometinib-d is the deuterium labeled Luvometinib (HY-159846). Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
    Luvometinib-d
  • HY-174683

    mRNA Cancer
    Human FLT4 mRNA encodes the human Fms related receptor tyrosine kinase 4 (FLT4) protein, a tyrosine kinase receptor for vascular endothelial growth factors C and D. FLT4 is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium.
    Human FLT4 mRNA
  • HY-137813S

    Isotope-Labeled Compounds PERK Neurological Disease Metabolic Disease Cancer
    PERK-IN-4-d3 is the deuterium labeled PERK-IN-4. PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states .
    PERK-IN-4-d3
  • HY-13502S

    Mitozantrone-d8; NSC 301739-d8

    Isotope-Labeled Compounds Topoisomerase PKC Cancer
    Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM .
    Mitoxantrone-d8
  • HY-118442

    Tetradecasphing-4-enine

    PKC Cancer
    Sphingosine (d14:1) (Tetradecasphing-4-enine), a sphingolipid, is a potent Protein kinase C (PKC) inhibitor. Sphingosine (d14:1) prevents its interaction with sn-1,2-diacylglycerol (DAG)/Phorbol esters .
    Sphingosine (d14:1)
  • HY-103097

    Phospholipase Others
    ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
    ST271
  • HY-121708

    c-Kit Cancer
    KI-328 is a novel inhibitor targeting KIT kinase that has selective activity against some KIT mutant kinases commonly found in acute myeloid leukemia (AML). KI-328 showed specificity for KIT kinase in in vitro kinase assays and inhibited the growth of wild-type (Wt) and mutant KIT-expressing cells, but had lower activity against D816V-KIT. Comparative analysis of the inhibitory effects of several potent KIT inhibitors on the growth of multiple mutant KIT-expressing cells showed that the multi-kinase inhibitors had comparable activity against D816V-KIT as against other mutant KITs; however, heat shock protein 90 (HSP90) inhibitors showed significant activity against D816V-KIT, inhibiting the growth of D816V-KIT-expressing cells at concentrations that did not affect the growth of other mutant KIT-expressing cells. These results suggest that potent KIT inhibitors have different activities against different types of KIT mutant kinases. Therefore, in clinical development, KIT inhibitors need to validate their activity against multiple types of KIT mutant kinases.
    KI-328
  • HY-142671

    ATM/ATR Cancer
    ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .
    ATR-IN-5
  • HY-115932

    Aurora Kinase Apoptosis Cancer
    Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents .
    Aurora kinase-IN-1
  • HY-131962

    PKD Metabolic Disease Cancer
    PKD-IN-1 (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as PKD-1 inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research .
    PKD-IN-1
  • HY-131962A

    PDK-1 Metabolic Disease Cancer
    PKD-IN-1 dihydrochloride (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as PKD-1 inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research .
    PKD-IN-1 dihydrochloride
  • HY-N10411

    Reverse Transcriptase HIV Xanthine Oxidase Infection Cardiovascular Disease Cancer
    Morin 3-O-β-D-glucopyranoside is a natural flavonoid with antifungal, anticancer and antioxidant activities. Morin 3-O-β-D-glucopyranoside inhibits reverse transcriptase, protein-tyrosine kinase and xanthine oxidase, and also shows anti-HIV, antiarteriosclerotic, and superoxide scavenging activities .
    Morin 3-O-β-D-glucopyranoside
  • HY-112096S

    NXP900-d5

    Src Isotope-Labeled Compounds Cancer
    eCF506-d5 (NXP900-d5) is deuterated labeled eCF506 (HY-112096). eCF506 is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer .
    eCF506-d5
  • HY-13941
    1-Naphthyl PP1
    1 Publications Verification

    1-NA-PP 1

    Src PKD Cancer
    1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
    1-Naphthyl PP1
  • HY-16305S1

    1263W94-d6 TFA; BW1263W94-d6 TFA; GW257406X-d6 TFA

    Bacterial Infection
    Maribavir-d6 TFA (1263W94-d6 TFA; BW1263W94-d6 TFA; GW257406X-d6 TFA) is a deuterium labeled Maribavir (HY-16305). Maribavir is an orally active antiviral agent for cytomegalovirus (CMV) through inhibition of protein kinase UL97 and the following CMV DNA replication .
    Maribavir-d6 TFA
  • HY-15463S2

    STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride

    Autophagy Bcr-Abl c-Kit SARS-CoV PDGFR Cancer
    Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
    Imatinib-d3 hydrochloride
  • HY-15463S3

    STI571-13C,d3; CGP-57148B-13C,d3

    Isotope-Labeled Compounds Autophagy SARS-CoV Bcr-Abl PDGFR c-Kit Cancer
    Imatinib- 13C,d3 (STI571- 13C,d3) is 13C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib-13C,d3
  • HY-146268

    CaMK Neurological Disease
    CaMKIIα-IN-1 (Compound 4d) is an orally active Ca 2+/calmodulin-dependent protein kinase II α (CaMKIIα) inhibitor with a KD of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .
    CaMKIIα-IN-1
  • HY-10230S

    PKC412-d5; CGP 41251-d5

    Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit Cancer
    Midostaurin-d5 (PKC412-d5) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM .
    Midostaurin-d5
  • HY-121037

    EGM1

    Phosphodiesterase (PDE) Cancer
    Eggmanone (EGM1) is a potent and selective phosphodiesterase 4 (PDE4) antagonist with an IC50 of 72 nM for PDE4D3. Eggmanone shows approximately 40- to 50-fold selective for PDE4D3 over other PDEs. Eggmanone exerts its Hh-inhibitory effects through selective antagonism of PDE4, leading to protein kinase A activation and subsequent Hh blockade .
    Eggmanone
  • HY-128142

    PKD PKC Cardiovascular Disease
    PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .
    PKC/PKD-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: